Zeus Capital has acted as co-manager to Bone Therapeutics on its â‚¬32.2m Euronext Brussels and Euronext Paris IPO, resulting in a market capitalisation of approximately â‚¬105 million.
Belgium-based Bone Therapeutics is a leader in bone cell therapy, addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention. The proceeds from the IPO will finance the development of Bone Therapeutics’ innovative bone cell therapy products and consolidate the company’s leadership in bone cell therapy, particularly in fracture repair and fracture prevention.
The transaction was oversubscribed by 2.5x, with 44 per cent of the institutional placement subscribed by Belgian investors and 56 per cent by international investors primarily based in France, the UK, Scandinavia and the Netherlands.
Dominic Wilson, Head of Healthcare at Zeus Capital, said: "Zeus is very pleased to have acted as co-manager to Bryan Garnier on the IPO of Bone Therapeutics on Euronext. Bone Therapeutics has a leading-edge technology with the potential to help meet an unmet medical need in the field of bone fracture repair and fracture prevention. Additionally, this IPO marks Zeus Capital’s first involvement in a listing on Euronext Brussels and Euronext Paris."